Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018162749) ANTIBODIES AGAINST PD-L1
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2018/162749 International Application No.: PCT/EP2018/055977
Publication Date: 13.09.2018 International Filing Date: 09.03.2018
IPC:
C07K 16/10 (2006.01) ,C07K 16/28 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08
against material from viruses
10
from RNA viruses
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
Applicants:
GENMAB A/S [DK/DK]; Kalvebod Brygge 43 1560 Copenhagen V, DK
Inventors:
ALTINTAS, Isil; NL
SATIJN, David; NL
VAN DEN BRINK, Edward; NL
VERZIJL, Dennis; NL
RADEMAKER, Rik; NL
PARREN, Paul; NL
DE GOEIJ, Bart; NL
Agent:
GENMAB A/S; Kalvebod Brygge 43 1560 Copenhagen V, DK
Priority Data:
PA 2017 0016409.03.2017DK
PA 2017 0040811.07.2017DK
Title (EN) ANTIBODIES AGAINST PD-L1
(FR) ANTICORPS DIRIGÉS CONTRE PD-L1
Abstract:
(EN) The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
(FR) La présente invention concerne de nouveaux anticorps et leur utilisation en médecine. L'invention concerne particulièrement, des anticorps bispécifiques capables de se lier à PD-L1 humain et capables de se lier à CD3 humain. L'invention concerne également de nouvelles classes d'anticorps capables de se lier à PD-L1 humain. L'invention concerne en outre des utilisations des anticorps de l'invention et des procédés, des constructions d'acide nucléique et des cellules hôtes pour produire des anticorps de l'invention.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)